The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|19|20|3337-3352

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.19, Iss.20, 2012-07, pp. : 3337-3352

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer

By  

Current Cancer Drug Targets, Vol. 12, Iss. 3, 2012-03 ,pp. : 237-246

Bentham Science Publishers

Access to resources Recommend Favorite

The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making

By  

Current Medicinal Chemistry, Vol. 17, Iss. 11, 2010-04 ,pp. : 1030-1038

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-01 ,pp. : 1263-1272

Bentham Science Publishers

Access to resources Recommend Favorite

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer

By de Mello Ramon Andrade   Madureira Pedro   Carvalho Liliana S   Araújo António   O’Brien Mary   Popat Sanjay  

Pharmacogenomics, Vol. 14, Iss. 14, 2013-11 ,pp. : 1765-1777

Future Medicine

Access to resources Recommend Favorite

Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer

By  

Current Cancer Drug Targets, Vol. 15, Iss. 9, 2015-11 ,pp. : 792-802

Bentham Science Publishers

Access to resources Recommend Favorite